...
search icon
cnta-img

Centessa Pharmaceuticals PLC ADR, Common Stock

CNTA

NSQ

$12.87

+$0.25

(1.98%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.67B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
726.68K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.54
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.75 L
$19.09 H
$12.87

About Centessa Pharmaceuticals PLC ADR, Common Stock

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCNTASectorS&P500
1-Week Return2.88%-1.91%-1.87%
1-Month Return-1.23%-3.82%8.93%
3-Month Return-17.82%-11.56%-2.39%
6-Month Return-24.74%-10.21%-2.41%
1-Year Return54.13%-9.91%10.88%
3-Year Return186.64%-0.28%46.93%
5-Year Return-40.83%31.29%94.89%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue---6.85M-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-33.99K130.92K786.58K942.40K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":3.61,"profit":true},{"date":"2022-12-31","value":13.89,"profit":true},{"date":"2023-12-31","value":83.47,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit-(33.99K)(130.92K)6.85M-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.5,"profit":false},{"date":"2022-12-31","value":-1.91,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin--(Infinity%)100.00%-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses10.44M139.28M210.28M178.14M201.06M[{"date":"2020-12-31","value":4.96,"profit":true},{"date":"2021-12-31","value":66.23,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.71,"profit":true},{"date":"2024-12-31","value":95.61,"profit":true}]
Operating Income(10.44M)(139.31M)(212.26M)(171.28M)(201.06M)[{"date":"2020-12-31","value":-1044000000,"profit":false},{"date":"2021-12-31","value":-13931440000,"profit":false},{"date":"2022-12-31","value":-21226300000,"profit":false},{"date":"2023-12-31","value":-17128300000,"profit":false},{"date":"2024-12-31","value":-20105500000,"profit":false}]
Total Non-Operating Income/Expense(601.00K)-(11.72M)(6.82M)(28.03M)[{"date":"2020-12-31","value":-60100000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1172400000,"profit":false},{"date":"2023-12-31","value":-681500000,"profit":false},{"date":"2024-12-31","value":-2803000700,"profit":false}]
Pre-Tax Income(10.66M)(381.74M)(216.95M)(176.14M)(233.01M)[{"date":"2020-12-31","value":-1066300000,"profit":false},{"date":"2021-12-31","value":-38174051100,"profit":false},{"date":"2022-12-31","value":-21695400000,"profit":false},{"date":"2023-12-31","value":-17614100000,"profit":false},{"date":"2024-12-31","value":-23301100700,"profit":false}]
Income Taxes378.00K113.99K(747.00K)(25.06M)2.84M[{"date":"2020-12-31","value":13.29,"profit":true},{"date":"2021-12-31","value":4.01,"profit":true},{"date":"2022-12-31","value":-26.27,"profit":false},{"date":"2023-12-31","value":-881.01,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(11.04M)-(216.21M)(151.09M)(235.86M)[{"date":"2020-12-31","value":-1104100000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-21620700000,"profit":false},{"date":"2023-12-31","value":-15108500000,"profit":false},{"date":"2024-12-31","value":-23585500700,"profit":false}]
Income From Continuous Operations(10.66M)-(216.21M)(157.42M)(235.76M)[{"date":"2020-12-31","value":-1066300000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-21620700000,"profit":false},{"date":"2023-12-31","value":-15742100000,"profit":false},{"date":"2024-12-31","value":-23575700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(11.04M)(381.85M)(216.21M)(151.09M)(235.76M)[{"date":"2020-12-31","value":-1104100000,"profit":false},{"date":"2021-12-31","value":-38185449800,"profit":false},{"date":"2022-12-31","value":-21620700000,"profit":false},{"date":"2023-12-31","value":-15108500000,"profit":false},{"date":"2024-12-31","value":-23575700000,"profit":false}]
EPS (Diluted)(4.97)(1.90)(2.31)(1.57)(1.73)[{"date":"2020-12-31","value":-496.85,"profit":false},{"date":"2021-12-31","value":-190,"profit":false},{"date":"2022-12-31","value":-231,"profit":false},{"date":"2023-12-31","value":-157,"profit":false},{"date":"2024-12-31","value":-173.49,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CNTA
Cash Ratio 11.76
Current Ratio 14.37

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CNTA
ROA (LTM) -28.58%
ROE (LTM) -74.44%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CNTA
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CNTA
Trailing PE NM
Forward PE NM
P/S (TTM) 114.65
P/B 4.45
Price/FCF NM
EV/R 103.54
EV/Ebitda 1.12

FAQs

What is Centessa Pharmaceuticals PLC ADR share price today?

Centessa Pharmaceuticals PLC ADR (CNTA) share price today is $12.87

Can Indians buy Centessa Pharmaceuticals PLC ADR shares?

Yes, Indians can buy shares of Centessa Pharmaceuticals PLC ADR (CNTA) on Vested. To buy Centessa Pharmaceuticals PLC ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CNTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Centessa Pharmaceuticals PLC ADR be purchased?

Yes, you can purchase fractional shares of Centessa Pharmaceuticals PLC ADR (CNTA) via the Vested app. You can start investing in Centessa Pharmaceuticals PLC ADR (CNTA) with a minimum investment of $1.

How to invest in Centessa Pharmaceuticals PLC ADR shares from India?

You can invest in shares of Centessa Pharmaceuticals PLC ADR (CNTA) via Vested in three simple steps:

  • Click on Sign Up or Invest in CNTA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Centessa Pharmaceuticals PLC ADR shares
What is Centessa Pharmaceuticals PLC ADR 52-week high and low stock price?

The 52-week high price of Centessa Pharmaceuticals PLC ADR (CNTA) is $19.09. The 52-week low price of Centessa Pharmaceuticals PLC ADR (CNTA) is $7.75.

What is Centessa Pharmaceuticals PLC ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Centessa Pharmaceuticals PLC ADR (CNTA) is 4.45

What is the Market Cap of Centessa Pharmaceuticals PLC ADR?

The market capitalization of Centessa Pharmaceuticals PLC ADR (CNTA) is $1.67B

What is Centessa Pharmaceuticals PLC ADR’s stock symbol?

The stock symbol (or ticker) of Centessa Pharmaceuticals PLC ADR is CNTA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top